Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

Item

http://www.wikidata.org/entity/Q39008165

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

@en

Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

@nl

type

Item

label

Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

@en

Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

@nl

prefLabel

Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

@en

Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

@nl

P1476

Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

@en

P2093

Frits A Wijburg

http://www.w3.org/2001/XMLSchema#string

Lodewijk IJlst

http://www.w3.org/2001/XMLSchema#string

Naomi van Vlies

http://www.w3.org/2001/XMLSchema#string

Sandra D K Kingma

http://www.w3.org/2001/XMLSchema#string

Tom Wagemans

http://www.w3.org/2001/XMLSchema#string

P2860

Orthopaedic management of Hurler's disease after hematopoietic stem cell transplantation: a systematic review.

Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses

Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway.

Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones.

Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses.

Synthetic genistein derivatives as modulators of glycosaminoglycan storage.

Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients.

P2888

s10545-014-9703-x

P304

813-821

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10545-014-9703-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24699889

http://www.w3.org/2001/XMLSchema#string